Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT04620733 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04620733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04620733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
April 21, 2021
Completion date
August 11, 2023
Enrollment
193 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis